Total Brain Ltd (ASX:TTB) is the developer of a neuroscience-based mental health monitoring and support platform powered by the largest standardised neuroscientific database in the world formed over almost two decades and with >$50m of R&D funding. The company has announced that it has entered into a perpetual, non-exclusive license with Johnson & Johnson (NYSE:JNJ) subsidiary, Janssen Research & Development LLC, for its iSPOT-D (International Study to Predict Optimised Treatment for Depression) research data, effective immediately. Janssen will pay Total Brain a one-time license fee of US$2.2m within 90 days. In an operational update to the market, CEO Matt Mund noted that Jansson was the third pharma company to license iSPOT. He also highlighted that in 2021, Total Brain had added 12 new clinical care centres, most of those in the past five months. Mr Mund has made the clinical care segment a primary focus for Total Brain’s corporate strategy, along with its population health partnerships, with the company targeting both one-time and subscription deals with pharma, addiction and behavioural health clinics. We have not altered our forecasts for FY22 but note that the Jansson deal underpins 65% of our H2FY22 forecasts. Our base-case valuation for Total Brain remains at $0.77/share.
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Janssen license further validates TTB's science
- Published:
23 Dec 2021 -
Author:
Finola Burke -
Pages:
7
Total Brain Ltd (ASX:TTB) is the developer of a neuroscience-based mental health monitoring and support platform powered by the largest standardised neuroscientific database in the world formed over almost two decades and with >$50m of R&D funding. The company has announced that it has entered into a perpetual, non-exclusive license with Johnson & Johnson (NYSE:JNJ) subsidiary, Janssen Research & Development LLC, for its iSPOT-D (International Study to Predict Optimised Treatment for Depression) research data, effective immediately. Janssen will pay Total Brain a one-time license fee of US$2.2m within 90 days. In an operational update to the market, CEO Matt Mund noted that Jansson was the third pharma company to license iSPOT. He also highlighted that in 2021, Total Brain had added 12 new clinical care centres, most of those in the past five months. Mr Mund has made the clinical care segment a primary focus for Total Brain’s corporate strategy, along with its population health partnerships, with the company targeting both one-time and subscription deals with pharma, addiction and behavioural health clinics. We have not altered our forecasts for FY22 but note that the Jansson deal underpins 65% of our H2FY22 forecasts. Our base-case valuation for Total Brain remains at $0.77/share.